Compare Adaptive Biotechnologies Corp (ADPT) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Li Auto Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.12 (market cap $4.04B), while Li Auto Inc trades at $12.61 (market cap $12.28B). The key difference: Li Auto Inc is far larger — about 3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | LI | |
|---|---|---|
Market Cap | $4.04B | $12.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $26.69 |
52-Week Low | $12.30 | $11.74 |
Enterprise Value | $4.10B | $1.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Li Auto (LI) trades at $12.84, down 0.85% on the day, with bearish technical signals and mixed earnings performance. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle launches including the Li L6 and L8 aim to boost deliveries amid intense Chinese EV competition.
While analyst consensus suggests moderate upside to $14.80 price target, significant risks include declining profitability, negative cash flow trends, and competitive pressures in China's EV market. The stock faces headwinds from execution challenges and macroeconomic uncertainties affecting the auto sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
